[
  {
    "ts": null,
    "headline": "Esperion Therapeutics: Little Upside Potential In Their Earlier Generation Drug",
    "summary": "Esperion Therapeutics has two approved LDL-C lowering therapies, Nexletol and Nexlizet, but lacks a strong pipeline for future growth.",
    "url": "https://finnhub.io/api/news?id=f49f82d88ee774759cfd86e64cf88a28fa806fd0621b66042831040269a658eb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740211994,
      "headline": "Esperion Therapeutics: Little Upside Potential In Their Earlier Generation Drug",
      "id": 132833341,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220627489/image_1220627489.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Esperion Therapeutics has two approved LDL-C lowering therapies, Nexletol and Nexlizet, but lacks a strong pipeline for future growth.",
      "url": "https://finnhub.io/api/news?id=f49f82d88ee774759cfd86e64cf88a28fa806fd0621b66042831040269a658eb"
    }
  }
]